The Two-Faced Cytokine IL-6 in Host Defense and Diseases.
The Two-Faced Cytokine IL-6 in Host Defense and Diseases.
复制标题
DOI:
10.3390/ijms19113528
复制
发表时间:
2018-11-09
影响因子:
5.6
通讯作者:
Kishimoto T
中科院分区:
文献类型:
--
作者:
Narazaki M;Kishimoto T
Interleukein-6 (IL-6), is produced locally from infectious or injured lesions and is delivered to the whole body via the blood stream, promptly activating the host defense system to perform diverse functions. However, excessive or sustained production of IL-6 is involved in various diseases. In diseases, the IL-6 inhibitory strategy begins with the development of the anti-IL-6 receptor antibody, tocilizumab (TCZ). This antibody has shown remarkable effects on Castleman disease, rheumatoid arthritis and juvenile idiopathic arthritis. In 2017, TCZ was proven to work effectively against giant cell arteritis, Takayasu arteritis and cytokine releasing syndrome, initiating a new era for the treatment of these diseases. In this study, the defensive functions of IL-6 and various pathological conditions are compared. Further, the diseases of which TCZ has been approved for treatment are summarized, the updated results of increasing off-label use of TCZ for various diseases are reviewed and the conditions for which IL-6 inhibition might have a beneficial role are discussed. Given the involvement of IL-6 in many pathologies, the diseases that can be improved by IL-6 inhibition will expand. However, the important role of IL-6 in host defense should always be kept in mind in clinical practice.
登录
查看更多内容
影响因子:
9.9
作者:
Araki M;Matsuoka T;Miyamoto K;Kusunoki S;Okamoto T;Murata M;Miyake S;Aranami T;Yamamura T
通讯作者:
Yamamura T
影响因子:
64.8
作者:
Bettelli, E;Carrier, YJ;Kuchroo, VK
通讯作者:
Kuchroo, VK
影响因子:
--
作者:
De Benedetti, Fabrizio;Rucci, Nadia;Teti, Anna
通讯作者:
Teti, Anna
影响因子:
27.4
作者:
Arima, K;Origuchi, T;Eguchi, K
通讯作者:
Eguchi, K
影响因子:
6.1
作者:
Chourbaji, Sabine;Urani, Alexandre;Gass, Peter
通讯作者:
Gass, Peter